From: A review on the role of cyclin dependent kinases in cancers
Tumor Type | Animal models | Results | References |
---|---|---|---|
Bladder cancer | female BALB/c nude mice | ∆ PVT1: ↓ tumor volume and tumor weight | [7] |
Breast cancer | 4–6-week-old female nude BALB/C mice | ↑↑ RBM7 (which up-regulates CDK1): ↑ proliferation, tumor growth | [19] |
6-week-old nude mice | ∆ KIAA1429 + CDK1: ↓ tumor weight | [10] | |
Cervical cancer | 4–6-week-old BALB/c nude mice | ↑↑ miR-143-3p or miR-495-3p: ↓ tumorigenicity | [20] |
∆ NCK1-AS1: ↓ tumor growth and tumor weight | [21] | ||
Cholangiocarcinoma | 5-week-old male BALB/cAnNCrj-nu/nu nude mice | ∆ CDK1: ↓ tumor growth | [56] |
Colorectal cancer | 5-week-old male BALB/c mice | dinaciclib and cobimetinib combination: ↓ tumor growth | [15] |
4-week-old male nude mice | ↑↑ miR-378a-5p: ↓ tumor growth by targeting CDK1 | [24] | |
4-week-old female BALB/c nude mice | ∆ DPP3: ↓ tumor growth | [25] | |
7-week-old BALB/c nude mice | ∆ SNHG4 (which regulated CDK1): ↓ tumor growth | [26] | |
female BALB/c nude mice | ∆ SNRPA1: ↓ tumor formation | [28] | |
Gastric cancer | 4-week-old male nude mice | ∆ ESRRA: ↓ tumor growth | [32] |
Hepatocellular carcinoma | NOD-SCID mice | Combination of RO3306 (CDK1 inhibitory substance) and sorafenib: ↓ tumor growth and ↓ sorafenib resistance | [37] |
BALB/c nude mice | ∆ DEPDC1B: ↓ tumor growth | [38] | |
nude mice | ↑↑ miR-1271-5p: ↓ tumor growth via targeting CDK1 | [39] | |
male nude mice | ∆ SNORD52: ↓ tumor growth and mass | [41] | |
Nasopharyngeal carcinoma | 5-week-old immunodeficient BALB/c nu/nu female mice | Tetrandrine treatment: ↑ radiosensitivity and ↓ tumor growth | [57] |
Ovarian cancer | ovarian xenograft mice | ∆ UBE2C: ↓ tumor growth | [59] |
4-week-old female BALB/c mice | ↑↑ DLEU1: ↑ tumor growth | [62] | |
Pancreatic cancer | NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice | AT7519 treatment: ↓ phosphorylation of CDK1, 2, 7, and 9 substrates and ↓ tumor growth | [63] |
Pancreatic ductal adenocarcinoma cancer | female C57BL/6 (KPC) or BALB/c (CT26) mic | FNG/dinaciclib combination therapy: ↑ CD8 + T cell-dependent antitumour activity | [65] |
Prostate cancer | nude mice | ∆ TPX2: ↓ tumor weight | [66] |
4-week-old male BALB/c immunodeficient nude mice | ↑↑ ABCC5: ↑ tumor volume and tumor weight | [67] |